Pinto António E, André Saudade, Laranjeira Cátia, Soares Jorge
Departamento de Patologia Morfológica, Instituto Português de Oncologia de Francisco Gentil, Centro Regional Oncológico de Lisboa, SA, Portugal.
Pathology. 2005 Feb;37(1):45-50. doi: 10.1080/00313020400011250.
The biological impact of cell cycle regulatory proteins on breast cancer progression is widely recognised, although mostly unclear. The aim of this preliminary study was to investigate the correlations of several cell cycle modulators (p53, p21, pRb, and mdm2) and c-erbB-2 expression with cell proliferation markers (S-phase fraction [SPF] and Ki-67) and overall survival in breast cancer.
The series comprised 50 women with stage I-II invasive ductal breast carcinoma (median follow-up 87 months), who were selected for their tumour proliferative characteristics (15 low, 15 high, and 20 intermediate proliferative tumours). Tumour differentiation was assessed following the Nottingham grading criteria. Cell cycle regulators, oestrogen receptor status, and Ki-67 index were analysed by immunohistochemistry on paraffin embedded material (cut-offs 10%). c-erbB-2 was evaluated according to a standardised immunohistochemical assay and borderline cases were confirmed by FISH analysis. Ploidy and SPF were determined by DNA flow cytometry on frozen samples. Chi-square test and Fisher's exact test were applied to analyse the statistical significance of data.
Positive immunostaining was observed in nine (18%) p53+, 30 (60%) p21+, 13 (26%) pRb+, and one (2%) mdm2+ cases. c-erbB-2 expression was considered positive in 11 (22%) cases. In the subset of patients dead of the disease, a high incidence of c-erbB-2 over-expression (7/10, 70%) was verified. In general, no significant correlations among cell cycle regulators or between the latter and histopathological or proliferative characteristics were found. Only the p53-/p21+ phenotype significantly correlated with low SPF (p=0.048), and p21 positivity showed a trend to be associated with low SPF (p=0.083). No statistically significant correlations between cell cycle inhibitors and clinical outcome were found. On the contrary, c-erbB-2 over-expression showed significant correlations with DNA aneuploidy (p<0.001), high SPF (p<0.001), high tumour grading (p=0.008), lack of oestrogen receptors (p=0.036), and poor overall survival (p<0.001).
The results seem to indicate the lack of correlations of cell cycle regulatory proteins with cell proliferation markers and overall survival in breast cancer, in contrast to c-erbB-2 over-expression which was found to be associated with increased proliferation rate and worse prognosis.
细胞周期调节蛋白对乳腺癌进展的生物学影响已得到广泛认可,尽管大多仍不明确。本初步研究的目的是探讨几种细胞周期调节因子(p53、p21、pRb和mdm2)以及c-erbB-2表达与乳腺癌细胞增殖标志物(S期分数[SPF]和Ki-67)及总生存期之间的相关性。
该系列研究包括50例I-II期浸润性导管癌女性患者(中位随访时间87个月),这些患者因其肿瘤增殖特征被选入研究(15例低增殖性肿瘤、15例高增殖性肿瘤和20例中等增殖性肿瘤)。根据诺丁汉分级标准评估肿瘤分化程度。采用免疫组织化学方法在石蜡包埋材料上分析细胞周期调节因子、雌激素受体状态和Ki-67指数(临界值为10%)。根据标准化免疫组织化学检测评估c-erbB-2,并通过荧光原位杂交分析(FISH)确诊临界病例。采用DNA流式细胞术在冰冻样本上测定倍体和SPF。应用卡方检验和Fisher精确检验分析数据的统计学意义。
在9例(18%)p53阳性、30例(60%)p21阳性、13例(26%)pRb阳性和1例(2%)mdm2阳性病例中观察到阳性免疫染色。11例(22%)病例的c-erbB-2表达被认为呈阳性。在死于该疾病的患者亚组中,证实c-erbB-2过表达的发生率较高(7/10,70%)。总体而言,未发现细胞周期调节因子之间或细胞周期调节因子与组织病理学或增殖特征之间存在显著相关性。仅p53阴性/p21阳性表型与低SPF显著相关(p=0.048),且p21阳性显示出与低SPF相关的趋势(p=0.083)。未发现细胞周期抑制剂与临床结局之间存在统计学显著相关性。相反,c-erbB-2过表达与DNA非整倍体(p<0.001)、高SPF(p<0.001)、高肿瘤分级(p=0.008)、缺乏雌激素受体(p=0.036)及总生存期较差(p<0.001)显著相关。
结果似乎表明细胞周期调节蛋白与乳腺癌细胞增殖标志物及总生存期之间缺乏相关性,与此相反,c-erbB-2过表达与增殖率增加和预后较差相关。